[Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem   cell transplantation in the treatment of drug-resistant Hodgkin disease].
In 1995-1999, 67 patients with relapsed Hodgkin's disease or refractory to chemotherapy (group A--first relapse, B--primary refractory disease, and C--repeated relapse) received cytoreductive (dexaBEAM, DHAP) therapy followed by high-dose BEAM chemotherapy and autologous bone marrow or blood cell transplantation. Early postoperative transplant-related mortality rate was 4.5%. At day 100, complete remission rates were: group A--95.6%; B--74.1%; and C--76.5%. Survival for all patients was: overall--61.9%; event-free--43.9%; disease-free--46%; and relapse-free survival--49.5%. Such factors as primary refractory disease, age over 30 years and response to cytoreductive therapy had significant influence on overall survival prognosis.
Uss
A L
AL
Byelorussian Center For Bone Marrow Transplantation, Minsk.
Zmachinskiĭ
V A
VA
Milanovich
N F
NF
Skriagin
A E
AE
Dziuba
E V
EV
Vlasenkova
S V
SV
Solov'eva
N S
NS
Batan
Z E
ZE
Mitskevich
P B
PB
Zavgorodniaia
I L
IL
Aleĭnikova
O V
OV
Zhavrid
E A
EA
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D008558:Melphalan; D002330:Carmustine
Mesto vysokodoznoĭ BEAM-terapii i autologichnoĭ transplantatsii  gemopoéticheskikh kletok u bol'nykh khimiorezistentnymi formami  bolezni Khodzhkina.